Ligand Prescription drugs Included LGND and Channel Therapeutics Company CHRO on Thursday signed a definitive merger settlement to mix Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. (collectively Pelthos) with CHRO Merger Sub Inc., a completely owned subsidiary of Channel.
The merger can be supported by $50 million in capital raised from a bunch of strategic buyers led by Murchinson.
Underneath the merger settlement, Channel will purchase 100% of Pelthos’ issued and excellent fairness pursuits, change its title to Pelthos Therapeutics, and commerce on the NYSE American alternate underneath the ticker PTHS.
Additionally Learn: Analyst Sees Massive Upside In Ligand’s Capital-Environment friendly Biotech Technique
In reference to the transaction, Ligand has agreed to take a position $18 million within the mixed firm, and the Investor Group has agreed to take a position $32 million in a complete of $50 million.
Upon finishing the transaction, Scott Plesha, CEO of Pelthos, will grow to be CEO of the mixed firm, and Frank Knuettel II, CEO of Channel Therapeutics, will grow to be CFO. The transaction is predicted to shut in the summertime of 2025.
The mixed firm will initially concentrate on accelerating the commercialization of Pelthos’ Zelsuvmi (berdazimer) topical gel, 10.3%, for Molluscum contagiosum infections in adults and pediatric sufferers one yr and older.
The U.S. Meals and Drug Administration (FDA) permitted Zelsuvmi in 2024. It’s the first and solely prescription remedy for molluscum infections permitted to be used at residence by sufferers, mother and father, and caregivers.
Ligand is entitled to a 13% royalty on worldwide gross sales of Zelsuvmi.
The mixed firm may also retain Channel’s present NaV 1.7 improvement applications for varied sorts of power ache, acute and power eye ache, and post-surgical nerve blocks.
In December 2024, Channel Therapeutics introduced that it achieved its endpoints in two pre-clinical in vivo fashions of the corporate’s nerve block formulations for acute ache, displaying materials enchancment in efficacy and period over the prevailing customary of care, bupivacaine.
An replace on the Channel’s animal efficacy examine for its eye ache program can be forthcoming.
“This transaction presents a compelling alternative to launch a commercial-ready product, with vital monetary backing from Murchinson, that has the potential to ship each close to and long-term worth to our shareholders,” stated Todd Davis, CEO of Ligand.
Frank Knuettel II, CEO of Channel Therapeutics, commented, “We now have carried out in depth due diligence on the Zelsuvmi market alternative and their group and operations, and we imagine that is a unprecedented alternative for present Channel shareholders. Strategically, it gives the potential for near-term income era from an FDA-approved drug, the chance to advance Channel’s present NaV 1.7 applications, and expanded capitalization from sturdy, long-standing buyers.”
Molluscum contagiosum is a poxvirus and one of the vital frequent pores and skin infections, afflicting an estimated 16.7 million folks within the U.S.
Worth Motion: LGND inventory is up 2.08% at $106.80 throughout the premarket session on the final test Thursday, and CHRO inventory closed at $1.26 on Wednesday.
Learn Subsequent:
Market Information and Information dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
